Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

NCT00434967 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2207

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Candesartan cilexetil
DRUG: Hydrochlorothiazide
DRUG: Candesartan/HCT 32/25 mg

Sponsor

AstraZeneca